









Markets
/
Stocks
/
nasdaq-ppbt
/

Purple Biotech Ltd

PPBT



View Detailed Chart

0.706USD

-0.009-1.22%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

6.38MMarket Cap

LossP/E TTM



Purple Biotech Ltd

0.706

-0.009-1.22%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.22%

5 Days

-5.24%

1 Month

-14.15%

6 Months

-69.58%

Year to Date

-84.95%

1 Year

-81.53%

View Detailed Chart

TradingKey Stock Score of Purple Biotech Ltd

Currency: USD Updated: 2025-12-24

Key Insights

Purple Biotech Ltd's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 200/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.00.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Purple Biotech Ltd's Score

Industry at a Glance

Industry Ranking

200 / 404

Overall Ranking

352 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

34.000

Target Price

+4146.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Purple Biotech Ltd Highlights

StrengthsRisks

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Overvalued

The company’s latest PE is -2.26, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 355.08K shares, increasing 21.76% quarter-over-quarter.